home icon

News

February 20, 2018

FDA Grants Humanitarian Use Designation for Nativis Voyager® Pediatric System

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

November 7, 2017

Nativis Research Partners to Present at the Society for Neuro-Oncology Annual Meeting in San Francisco

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

October 23, 2017

CEO Chris Rivera details Nativis’ successes and future goals

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

October 17, 2017

Nativis Research Partner to Present at COGNO Conference in Australia

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

October 3, 2017

Nativis Announces Engagement of Strategic Financial Advisory Firm Outcome Capital, LLC

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

September 20, 2017

Nativis to Present at the Ladenburg Thalmann 2017 Healthcare Conference

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

September 12, 2017

Nativis Announces Expanded Clinical Program in Glioblastoma Multiforme

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

August 23, 2017

Nativis to Present at 19th Annual Rodman & Renshaw Global Investment Conference

Read More
Nativis Research Partner to Present at COGNO Conference in Australia

May 30, 2017

Nativis Publishes Proof of Concept Paper Using Voyager® System to Inhibit Enzyme in Algae

Read More

May 18, 2017

Nativis Expands C-Suite with the Addition of Dr. Kenneth Ferguson as Chief Scientific Officer

Read More
Older » « Newer

EMulate Therapeutics Voyager® ulRFE® System for rGBM is an investigational medical device. Limited by United States law to investigational use only.

© EMulate Therapeutics 2019. All rights reserved.